MX391180B - Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo - Google Patents

Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo

Info

Publication number
MX391180B
MX391180B MX2019005379A MX2019005379A MX391180B MX 391180 B MX391180 B MX 391180B MX 2019005379 A MX2019005379 A MX 2019005379A MX 2019005379 A MX2019005379 A MX 2019005379A MX 391180 B MX391180 B MX 391180B
Authority
MX
Mexico
Prior art keywords
preparation
pyrazolo
medical use
heteroaryl derivative
derivative
Prior art date
Application number
MX2019005379A
Other languages
English (en)
Other versions
MX2019005379A (es
Inventor
Chunfeng Shu
Feng He
Guobao Zhang
Qiyue Hu
Weikang Tao
Original Assignee
Jiangsu Hengrui Medicine Co
Shanghai hengrui pharmaceutical co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co, Shanghai hengrui pharmaceutical co ltd filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2019005379A publication Critical patent/MX2019005379A/es
Publication of MX391180B publication Critical patent/MX391180B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen un derivado de pirazolo-heteroarilo, un método de preparación y su uso médico. En particular, la presente invención se refiere a un nuevo derivado de pirazolo-heteroarilo como el mostrado en la fórmula general (I), a un método de preparación del mismo y a una composición farmacéutica que contiene el derivado y a su uso como agente terapéutico, en particular como agonista de TLR7, en donde cada sustituyente en la fórmula general (I) se define en la descripción.
MX2019005379A 2016-11-28 2017-11-27 Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo MX391180B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201611066071 2016-11-28
PCT/CN2017/113007 WO2018095426A1 (zh) 2016-11-28 2017-11-27 吡唑并杂芳基类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
MX2019005379A MX2019005379A (es) 2019-09-04
MX391180B true MX391180B (es) 2025-03-21

Family

ID=62194797

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005379A MX391180B (es) 2016-11-28 2017-11-27 Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo

Country Status (16)

Country Link
US (2) US11117898B2 (es)
EP (1) EP3546457B1 (es)
JP (1) JP7145854B2 (es)
KR (1) KR20190084991A (es)
CN (1) CN108884092B (es)
AU (1) AU2017366621B2 (es)
BR (1) BR112019010182A2 (es)
CA (1) CA3044903A1 (es)
ES (1) ES2886973T3 (es)
HU (1) HUE054964T2 (es)
MX (1) MX391180B (es)
MY (1) MY192084A (es)
PT (1) PT3546457T (es)
RU (1) RU2748833C2 (es)
TW (1) TWI760390B (es)
WO (1) WO2018095426A1 (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230010826A (ko) 2016-10-14 2023-01-19 프리시젼 바이오사이언시스 인코포레이티드 B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
JP7037667B2 (ja) 2017-12-20 2022-03-16 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. Stingアダプタータンパク質を活性化するホスホン酸結合を有する3’3’環状ジヌクレオチド
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ, インコーポレイテッド Hbv複製阻害剤としての置換ピロリジン化合物
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2,2,─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
CN110526917B (zh) * 2018-05-25 2021-09-03 江苏恒瑞医药股份有限公司 一种吡唑并杂芳基类衍生物的可药用盐、晶型及其制备方法
CN110526918B (zh) * 2018-05-25 2021-09-03 江苏恒瑞医药股份有限公司 一种吡唑并杂芳基类衍生物的晶型及制备方法
MX2020012651A (es) * 2018-05-25 2021-02-02 Jiangsu Hengrui Medicine Co Forma de cristal de clorhidrato de derivado de pirazoloheteroarilo, y metodo de preparacion.
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
US11554120B2 (en) * 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
WO2020063858A1 (zh) * 2018-09-29 2020-04-02 江苏恒瑞医药股份有限公司 Tlr激动剂与免疫检查点抑制剂联合在制备治疗肿瘤的药物中的用途
WO2020073942A1 (zh) * 2018-10-11 2020-04-16 江苏恒瑞医药股份有限公司 一种tlr7激动剂前药、其制备方法及其在医药上的应用
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
KR102853071B1 (ko) 2019-02-07 2025-09-02 베이진 엘티디 Tlr7 작용제로서의 이미다조[2,1-f][1,2,4]트리아진-4-아민 유도체
BR112021015577A2 (pt) 2019-02-08 2021-10-05 Research & Business Foundation Sungkyunkwan University Complexo-colesterol agonista do receptor toll-like 7 ou 8 e uso do mesmo
CN113574063B (zh) 2019-03-07 2025-03-18 捷克共和国有机化学与生物化学研究所 3’3’-环二核苷酸及其前药
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020178769A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
CN112007034B (zh) * 2019-05-31 2022-05-24 江苏恒瑞医药股份有限公司 Tlr激动剂与免疫检查点抑制剂、vegfr抑制剂联合在制备治疗肿瘤药物中的用途
WO2020259667A1 (zh) * 2019-06-28 2020-12-30 江苏恒瑞医药股份有限公司 Tlr激动剂与抗ox40抗体或其抗原结合片段联合在制备治疗肿瘤的药物中的用途
JP7595643B2 (ja) 2019-08-02 2024-12-06 ベイジーン リミテッド Tlr8アゴニストとしてのイミダゾ[2,1-f][1,2,4]トリアジン-4-アミン誘導体
US20220296619A1 (en) 2019-08-19 2022-09-22 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
HRP20241379T1 (hr) 2019-09-30 2024-12-20 Gilead Sciences, Inc. Cjepiva za hbv i postupci za liječenje hbv
CN112830929B (zh) * 2019-11-22 2022-09-16 江苏恒瑞医药股份有限公司 吡唑并杂芳基类化合物的制备方法
US12410418B2 (en) 2019-12-06 2025-09-09 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
KR20220132594A (ko) * 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
CN115210235A (zh) * 2020-01-27 2022-10-18 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
CN115279765B (zh) * 2020-01-27 2024-11-12 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
WO2021154662A1 (en) * 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
JP2023512206A (ja) * 2020-01-27 2023-03-24 ブリストル-マイヤーズ スクイブ カンパニー トール様受容体7(TLR7)アゴニストとしての1H-ピラゾロ[4,3-d]ピリミジン化合物
JP7684316B2 (ja) * 2020-01-27 2025-05-27 ブリストル-マイヤーズ スクイブ カンパニー トール様受容体7(TLR7)アゴニストとしての1H-ピラゾロ[4,3-d]ピリミジン化合物
CN115151547A (zh) * 2020-01-27 2022-10-04 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
US20230127326A1 (en) * 2020-01-27 2023-04-27 Bristol-Myers Squibb Company C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
JP7712941B2 (ja) * 2020-01-27 2025-07-24 ブリストル-マイヤーズ スクイブ カンパニー トール様受容体7(TLR7)アゴニストとしての1H-ピラゾロ[4,3-d]ピリミジン化合物
CN115666637A (zh) 2020-03-02 2023-01-31 蛋白科技先锋 基于病原体细胞壁骨架的模拟活病原体的纳米粒子及其制备方法
KR102987126B1 (ko) 2020-03-20 2026-07-07 길리애드 사이언시즈, 인코포레이티드 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법
CN113801136B (zh) * 2020-06-16 2023-04-07 江苏恒瑞医药股份有限公司 咪唑并杂芳基类衍生物、其制备方法及其在医药上的应用
EP4194008A4 (en) 2020-08-04 2025-01-08 Progeneer Inc. Kinetically acting adjuvant ensemble
US20230277525A1 (en) 2020-08-04 2023-09-07 Progeneer Inc Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof
WO2022031021A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적 제어가 가능한 아주번트를 포함하는 mrna 백신
CN114276351B (zh) * 2020-09-27 2023-06-16 江苏恒瑞医药股份有限公司 含氮杂环类衍生物、其制备方法及其在医药上的应用
CN114621230B (zh) * 2020-12-10 2023-06-16 江苏恒瑞医药股份有限公司 含氮杂环化合物、其制备方法及其在医药上的应用
US20240269142A1 (en) 2021-05-13 2024-08-15 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ, インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
US20250059183A1 (en) * 2021-12-08 2025-02-20 Shanghai Visonpharma Co., Ltd. Pyridine[4,3-d]pyrimidine compound as tlr7/8 agonist
CN119604504A (zh) * 2022-09-16 2025-03-11 四川科伦博泰生物医药股份有限公司 一类双并环化合物、其制备方法及用途
CN119367281A (zh) * 2023-07-27 2025-01-28 苏州申拓医药科技有限公司 一种tlr7/8激动剂注射剂、其制备方法及其用途
CN119431359A (zh) * 2023-07-28 2025-02-14 苏州申拓医药科技有限公司 一种tlr7/8激动剂的可药用盐、晶型及其制备方法、药物组合物和用途
WO2025110816A1 (ko) 2023-11-23 2025-05-30 프로지니어 주식회사 암의 치료를 위한 활성화 부위가 일시적으로 비활성화된 톨-유사 수용체 7 또는 8 작용자와 항암 치료의 병용요법
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
TW202608468A (zh) 2024-05-13 2026-03-01 美商基利科學股份有限公司 組合療法
US20250345390A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638967B2 (en) 2000-08-08 2003-10-28 Ortho-Mcneil Phamraceutical, Inc. Thiophene of furan pyrrolidine compounds
EP1667694B1 (en) 2003-09-05 2010-04-28 Anadys Pharmaceuticals, Inc. Tlr7 ligands for the treatment of hepatitis c
KR20080002866A (ko) * 2005-04-25 2008-01-04 노파르티스 아게 펩티드 데포르밀라제 (pdf) 억제제로서 유용한이미다조(1,2-a)피리딘 유도체
AU2007216247A1 (en) 2006-02-17 2007-08-23 Pfizer Limited 3 -deazapurine derivatives as TLR7 modulators
EP2040712B1 (en) 2006-07-18 2011-03-02 Anadys Pharmaceuticals, Inc. Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
EP2132209B8 (en) 2007-03-19 2014-04-16 AstraZeneca AB 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators
TW200902018A (en) * 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Novel adenine compound
EP2201013B1 (en) * 2007-09-14 2014-11-19 Universita Degli Studi di Siena New 4-substituted derivatives of pyrazolo [3,4-d] pyrimidine and pyrrolo [2,3-d] pyrimidine and uses thereof
WO2009062118A2 (en) * 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
US8865896B2 (en) 2008-01-17 2014-10-21 Astrazeneca Aktiebolag Method for preparing adenine compound
UY32306A (es) * 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
GB0908772D0 (en) 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
WO2011031965A1 (en) 2009-09-14 2011-03-17 Gilead Sciences, Inc. Modulators of toll-like receptors
BR112012009329A2 (pt) * 2009-10-22 2016-06-07 Gilead Sciences Inc derivados de purina ou deazapurina úteis para o tratamento de infecções virais (inter alia)
WO2012080730A1 (en) 2010-12-17 2012-06-21 Astrazeneca Ab Purine derivatives
KR101379808B1 (ko) 2012-04-03 2014-04-24 울산대학교 산학협력단 산화질소 생성 억제용 피라졸로피리미딘 유도체 화합물
EP3049086A4 (en) * 2013-09-27 2017-02-22 Nimbus Iris, Inc. Irak inhibitors and uses thereof
SG11201607586UA (en) * 2014-03-13 2016-10-28 Agency Science Tech & Res Fused pyrimidine-based hydroxamate derivatives
ES2804101T3 (es) 2014-04-22 2021-02-03 Hoffmann La Roche Compuestos de 4-amino-imidazoquinolina
CN105367576A (zh) * 2014-08-15 2016-03-02 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
CN112898308B (zh) * 2014-08-15 2026-08-07 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
ES2688194T3 (es) 2014-09-11 2018-10-31 Bristol-Myers Squibb Company Inhibidores de mieloperoxidasa de triazolopirimidina y triazolopiridina de tioéter

Also Published As

Publication number Publication date
TWI760390B (zh) 2022-04-11
MY192084A (en) 2022-07-26
ES2886973T3 (es) 2021-12-21
RU2748833C2 (ru) 2021-05-31
US20210380593A1 (en) 2021-12-09
EP3546457A4 (en) 2020-05-20
BR112019010182A2 (pt) 2019-09-17
PT3546457T (pt) 2021-08-06
US11117898B2 (en) 2021-09-14
RU2019118390A3 (es) 2020-12-28
US20210115046A1 (en) 2021-04-22
CN108884092B (zh) 2021-06-29
WO2018095426A1 (zh) 2018-05-31
KR20190084991A (ko) 2019-07-17
MX2019005379A (es) 2019-09-04
RU2019118390A (ru) 2020-12-28
JP7145854B2 (ja) 2022-10-03
TW201819387A (zh) 2018-06-01
CN108884092A (zh) 2018-11-23
AU2017366621B2 (en) 2021-07-29
EP3546457B1 (en) 2021-07-14
CA3044903A1 (en) 2018-05-31
JP2019535730A (ja) 2019-12-12
HUE054964T2 (hu) 2021-10-28
AU2017366621A1 (en) 2019-05-23
EP3546457A1 (en) 2019-10-02

Similar Documents

Publication Publication Date Title
MY192084A (en) Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
MX2021007432A (es) Compuestos y composiciones para inhibir la actividad de shp2.
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
PH12017502001A1 (en) Amido-substituted cyclohexane derivatives
MX368504B (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
GEP201706619B (en) New thienopyrimidine derivatives, a process for their preparation and pharmaceutical composition containing them
GEAP201914680A (en) New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
GEAP201914679A (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2020013785A (es) Derivado de la pirido-pirimidina, metodo de preparacion del mismo y uso medico del mismo.
PH12016500003A1 (en) Compounds and compositions as inhibitors of mek
NZ711424A (en) Pyridine derivatives as soft rock inhibitors
MX2020011818A (es) Derivados de piridincarboxamida, su metodo de preparacion y sus usos farmaceuticos.
PH12015501740A1 (en) Sodium channel modulators for the treatment of pain
MY206745A (en) Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
MY181641A (en) Amino pyran ring derivative and composition and use thereof
TW201613578A (en) Pharmaceutical combinations
PH12016502352A1 (en) Pharmaceutical composition
PH12018500378A1 (en) Novel annelated phenoxyacetamides
TN2016000490A1 (en) Naphthyridinedione derivatives.
PH12018502376B1 (en) Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
EA033423B1 (ru) Циклопропанбензофуранилпиридопиразиндионы
MX363622B (es) Nuevos derivados de amidinourea macrociclica, metodos de preparacion y usos de los mismos como inhibidores de quitinasa.